{"id":"W2564310149","doi":"10.1200/jco.2013.31.18_suppl.lba2009","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated <i>O<sup>6</sup>-methylguanine-DNA methyltransferase</i> (<i>MGMT</i>) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Temozolomide; Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Progression-free survival; Concomitant; Population; Radiation therapy; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010222,0.0009028392,0.001779276,0.0007656902,0.0003033382,0.0006587683,0.0007560325,0.0008519856,0.002073019],"category_scores_gemma":[0.000840998,0.0004589435,0.001231656,0.0006429324,0.0006818115,0.0007096934,0.0003082537,0.001762074,0.0003658878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001341375,"about_ca_system_score_gemma":0.00132454,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001399528,"about_ca_topic_score_gemma":0.005887794,"domain_scores_codex":[0.9996616,0.0001485797,0.00002963372,0.0000615104,0.00003590598,0.00006275871],"domain_scores_gemma":[0.9994724,0.00008216919,0.000158493,0.00003514894,0.00003334808,0.000218416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8863148,0.01889922,0.006066684,0.001048456,0.001804909,0.000117179,0.00009490938,0.0008836287,0.009677697,0.0001379749,0.002546298,0.07240823],"study_design_scores_gemma":[0.696799,0.2831295,0.0137727,0.00008201,0.001335951,0.0001419814,0.00004520323,0.0007231213,0.00173251,0.0001295141,0.002080329,0.00002824794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881259,0.007013466,0.0003493738,0.0005934516,0.0003323063,0.001422419,0.0006797836,0.00008199681,0.001401262],"genre_scores_gemma":[0.991899,0.003313699,0.0007499129,0.0006793037,0.0002229847,0.001246162,0.001104252,0.00001264251,0.0007720346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002073019,"threshold_uncertainty_score":0.009732366,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03613921631583751,"score_gpt":0.3676998514130878,"score_spread":0.3315606350972503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}